<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781582</url>
  </required_header>
  <id_info>
    <org_study_id>20-9518-BO</org_study_id>
    <nct_id>NCT04781582</nct_id>
  </id_info>
  <brief_title>LVRS Versus BLVR in Patients With Homogenous Emphysema, CLUB-HE Trial</brief_title>
  <official_title>Comparison of Lung Volume Reduction Surgery Versus Bronchoscopic Lung Volume Reduction in Patients With Homogenous Emphysema: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial comparing surgical and bronchoscopic lung&#xD;
      volume reduction in patients with advanced homogeneous emphysema suitable for both&#xD;
      procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung volume reduction surgery (LVRS) as well as bronchoscopic lung volume reduction (BLVR)&#xD;
      provide functional improvements in selected patients with homogenous emphysema and pronounced&#xD;
      hyperinflation. A direct comparison of LVRS and BLVR in patients with homogenous emphysema is&#xD;
      not available, thus the study will provide important data to guide treatment selection in&#xD;
      this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single center, 1:1 randomized, open label, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 compared to baseline (deltaFEV1)</measure>
    <time_frame>6 months post intervention</time_frame>
    <description>Percent change in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BODE Index (Body mass index, airflow obstruction, dyspnoea and exercise capacity in chronic obstructive pulmonary disease)</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>Combined score including BMI, FEV1, 6 MWT, MRC dyspnoea score; range 0 (best) - 10 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TLC</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>Percent change in Total Lung Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>Percent change in Residual Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV/TLC</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>Percent change in RV/TLC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLCO</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>Percent change in diffusion capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic pulmonary artery pressure</measure>
    <time_frame>6 months post intervention</time_frame>
    <description>measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related quality of life measured by SGRQ</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>St. George´s Respiratory Questionnaire (score 0-100, higher scores indicating more limitations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in respiratory health status measured by CAT</measure>
    <time_frame>3, 6 months post intervention</time_frame>
    <description>COPD Assessment Test (CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days post intervention</time_frame>
    <description>Number of deaths 30 days post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months post intervention</time_frame>
    <description>Percent of patients alive 6 months post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of (serious) adverse events</measure>
    <time_frame>Periprocedural, 1, 3, 6 months post intervention</time_frame>
    <description>Number of events periprocedural, 1, 3 and 6 months post intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Emphysema or COPD</condition>
  <arm_group>
    <arm_group_label>Lung volume reduction surgery arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral videothoracoscopic lung volume reduction surgery by wedge resection. Unilateral procedures are possible in case of severe adhesions or intraoperative instability. In these cases a staged approach with contralateral LVRS within 3 months is possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchoscopic lung volume reduction arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primarily unilateral bronchoscopic lung volume reduction by endobronchial valves. If a bilateral procedure is feasible it must be performed within 3 months after the first intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung volume reduction surgery</intervention_name>
    <description>Surgical lung volume reduction</description>
    <arm_group_label>Lung volume reduction surgery arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopic lung volume reduction</intervention_name>
    <description>Bronchoscopic lung volume reduction by endobronchial valves</description>
    <arm_group_label>Bronchoscopic lung volume reduction arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD III-IV&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  FEV1 &lt; 50% predicted after bronchodilatation&#xD;
&#xD;
          -  Significant hyperinflation (TLC &gt;100% predicted, RV &gt; 200% predicted, RV/TLC &gt; 60%)&#xD;
&#xD;
          -  Non-smoker or ex-smoker for &gt; 3 months (documented by cotinine testing)&#xD;
&#xD;
          -  6 MWT &gt;150 m and ≤ 450m&#xD;
&#xD;
          -  MRC dyspnea score &gt; 3&#xD;
&#xD;
          -  Homogenous emphysema as assessed by HR-CT (&lt; 15% difference in emphysema destruction&#xD;
             score between target lobe and ipsilateral lobe) [16, 17]&#xD;
&#xD;
          -  Uni- or bilateral collateral ventilation (CV) negative result assessed fissure&#xD;
             completeness&gt;95% in QCT and confirmed by a bronchoscopic procedure (Chartis©)&#xD;
&#xD;
          -  Optimal medical therapy for &gt; 3months, sufficient rehabilitation status with no need&#xD;
             for further training/rehabilitation or rehabilitation within 6 months prior to&#xD;
             intervention.&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 18, but &lt; 35 kg/m2&#xD;
&#xD;
          -  Daily dose of prednisone ≤ 10mg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication against either LVRS or BLVR and/or to surgery and bronchoscopy in&#xD;
             general&#xD;
&#xD;
          -  Major comorbidities limiting survival&#xD;
&#xD;
          -  Age ≥ 80 years&#xD;
&#xD;
          -  Nicotine abuse within 3 months (documented by cotinine testing)&#xD;
&#xD;
          -  Predominance of either left or right lung of &gt;70% in perfusion SPECT scintigraphy&#xD;
&#xD;
          -  FEV1 and/or DLCO &lt;20% predicted (post bronchodilatation)&#xD;
&#xD;
          -  Untreated Hypoxemia (PaO2 &lt; 50 mmHg)&#xD;
&#xD;
          -  Untreated Hypercapnia (PaCO2 &gt; 50 mmHg)&#xD;
&#xD;
          -  Significant pulmonary fibrosis or bronchiectasis&#xD;
&#xD;
          -  Destroyed/vanished lung on HR-CT&#xD;
&#xD;
          -  Previous chest surgery or bronchoscopic interventions&#xD;
&#xD;
          -  Pulmonary hypertension (sPAP &gt; 35 mmHg)&#xD;
&#xD;
          -  Active waiting list for lung transplantation&#xD;
&#xD;
          -  Patient is not able to understand and willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Aigner, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemens Aigner, Prof. MD</last_name>
    <phone>+49201433</phone>
    <phone_ext>4011</phone_ext>
    <email>clemens.aigner@rlk.uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaid Darwiche, Prof. MD</last_name>
    <phone>+49201433</phone>
    <phone_ext>4222</phone_ext>
    <email>kaid.darwiche@rlk.uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medicine Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Aigner, Prof. MD</last_name>
      <phone>+49201433</phone>
      <phone_ext>4011</phone_ext>
      <email>clemens.aigner@rlk.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Kaid Darwiche, Prof. MD</last_name>
      <phone>+49201433</phone>
      <phone_ext>4222</phone_ext>
      <email>kaid.darwiche@rlk.uk-essen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Clemens Aigner</investigator_full_name>
    <investigator_title>Professor of Thoracic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

